PMC6795279_01
CT scan after sunitinib therapy and while under nivolumab Pulmonary metastasis (A,B) and renal lesion (C) after progression under sunitinib. Radiological complete response of the pulmonary metastasis (D,E) under nivolumab therapy at 6 months. The CT scan showed only a 75 mm mass on the left kidney (F).
fonc-09-01033-g0001.jpg
PMC6795279_01_fonc-09-01033-g0001.jpg
F1
By February 2016, the patient's disease had progressed with new lung, pleural (Figures 1A-C), and bone metastases, and he was therefore offered inclusion in the GETUG-AFU 26-NIVOREN trial (NCT03013335). We observed a partial response after 3 months of treatment and complete response in the lungs (Figures 1D-F) and bone after 6 months.
Vitiligo lesions. Depigmentation of eyebrows (A), hair (B), and skin (C) observed after 8 months of treatment with nivolumab. Depigmentation affected the whole skin but preferentially the chest.
fonc-09-01033-g0002.jpg
PMC6795279_01_fonc-09-01033-g0002.jpg
F2
After 8 months of treatment with nivolumab, the patient developed a depigmentation of his eyebrows and hair that was suspected to be indicative of vitiligo (Figures 2A,B). As nivolumab was maintained the vitiligo spread further, affecting the eyelashes and skin over the entire body (Figure 2C).
Macroscopic and microscopic examination. Macroscopic examination (A): fibrosis alterations on upper pole of the kidney (arrow) Microscopic examination (B,C): fibrosis alterations with calcifications and without residual tumor cells. Stars indicate normal parenchyma.
fonc-09-01033-g0003.jpg
PMC6795279_01_fonc-09-01033-g0003.jpg
F3
Pathological analysis (Figure 3) revealed a lesion of 6 cm at the superior pole of the kidney with fibrosis, focally calcified, and without residual tumor cells.